Edalen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Edalen

What is Edalen? (Risperidone)

Property Description
Active ingredient Risperidone (INN)
Form Tablet, Oral Solution, Injectable Suspension
Pharmacological class Atypical Antipsychotic (Second-Generation)
General purpose Stabilizes thought processes and emotional regulation
Origin Synthetic Compound (Benzisoxazole derivative)

Edalen: A Second-Generation Antipsychotic (Definition and Type)

Edalen is a prescription-only medicine containing the sole active ingredient Risperidone. It is classified as an Atypical Antipsychotic, a term consistently applied to Second-Generation Antipsychotic (SGA) compounds in clinical practice. The general purpose of this medication is to support individuals in managing severe disturbances in their thinking, perception, and emotional experience. Risperidone's distinguishing factor within the antipsychotic class is its dual-action profile, recognized by global regulatory bodies for its ability to target both dopamine and serotonin receptors simultaneously.

Composition, Origin, and Available Forms of Risperidone

The active component, Risperidone, is a single-ingredient product synthesized as a benzisoxazole derivative. This medication is available in multiple pharmaceutical preparations, enabling flexible route of administration, including standard tablets, liquid oral solution, and a specialized injectable suspension for intramuscular administration. The existence of both oral and long-acting injectable forms represents a crucial differentiating factor for the medication, allowing treatment to be tailored to meet varied patient adherence and clinical needs.

Basic Principle: How Risperidone Balances Chemical Messengers

Edalen's therapeutic utility is achieved through its core mechanism principle of balancing chemical messengers—specifically dopamine and serotonin. Risperidone acts as a dual receptor antagonist, exerting a notable influence on the 5-HT2A serotonin receptor while simultaneously blocking the D2 dopamine receptor. This dual Serotonergic-Dopaminergic activity is the defining characteristic of the atypical class. By helping to normalize signaling in these pathways, the drug aims to reduce hyperactivity and disorganization in neural circuits, supporting the stabilization of thought and perception.

What side effects are possible with Edalen?

Possible side effects and safety information for Edalen (Risperidone)

The safety profile of Edalen is formally structured according to official government regulatory documentation, classifying potential adverse reactions by frequency, physiological system, and severity. This information describes the officially documented risks associated with the medicine.

Safety Entity Description
Adverse reaction scope Neurological/Psychiatric (movement disorders, sedation), Metabolic/Endocrine (weight changes, prolactin elevation), Cardiovascular (hypotension, heart conduction changes), and Infections (respiratory/urinary).
Frequency classification Very Common (ge 1/10) includes Somnolence/Sedation, Parkinsonism, Headache, and Insomnia. Common (ge 1/100 to <1/10) includes increased weight, Dizziness, Akathisia, Tachycardia, and Gastrointestinal symptoms like Nausea or Constipation. Rarer events include the risk of Neuroleptic Malignant Syndrome and Priapism.
System-organ classes involved Nervous System Disorders, Metabolism and Nutrition Disorders, Endocrine Disorders (Hyperprolactinemia), Vascular Disorders, and Cardiac Disorders are the primary systems cited in official labeling.
Serious adverse reactions Officially documented serious reactions include Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (TD), and Cerebrovascular Adverse Events (CVAE) (such as stroke or Transient Ischemic Attack).
Population-specific safety considerations Older Adults with Dementia-Related Psychosis: The regulatory label contains a safety restriction regarding an increased risk of death (predominantly from cardiovascular or infectious causes) and a higher incidence of CVAE in this population. Pediatric Population: Greater magnitude of Weight Gain and Hyperprolactinemia are documented concerns compared to adults.
Dose- or exposure-related patterns Initial Phase: Orthostatic Hypotension (dizziness upon standing) and acute Extrapyramidal Symptoms are more likely to occur early in treatment. Long-Term Use: Risk of developing Tardive Dyskinesia and significant Weight Gain is associated with chronic exposure.
Safety-related restrictions The drug is associated with Metabolic Changes (Hyperglycemia/Diabetes Mellitus, Dyslipidemia) and may impair cognitive and motor performance. Caution is advised regarding the potential disruption of body temperature regulation.

Regulatory safety summary

• The safety profile is characterized by frequent movement disorders and a required safety restriction for older adults with dementia-related psychosis. • The framework highlights both common neurological effects and less common but serious cardiovascular and metabolic complications. • Long-term safety concerns are officially documented, including the risk of Tardive Dyskinesia and persistent Hyperprolactinemia.

This structure reflects how the official safety information frames the documented risk of the medicine, without providing clinical advice or therapeutic guidance.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation classifies Edalen (Risperidone) overdose as capable of causing severe and potentially life-threatening outcomes, requiring immediate medical attention.

Key Component Official Regulatory Statement
Documented Manifestations Overdose may present with CNS effects such as drowsiness, sedation, depressed level of consciousness, and movement disorders including extrapyramidal symptoms (EPS) and convulsions. Cardiovascular effects include tachycardia and hypotension.
Severe Outcomes QT prolongation (a cardiac conduction abnormality), ventricular arrhythmia, coma, and respiratory depression.
Population-Specific Note Increased risk of accidental overdose is documented in pediatric patients due to potential medication errors involving the oral solution. Overdose symptoms, including severe EPS, may be more pronounced in children.

Official Overdose Statements:

  • Urgent Care Required: Suspected overdose necessitates that a person seek immediate medical attention due to the explicit risk of severe CNS and cardiovascular events documented in official labeling.
  • Antidote Status: No specific antidote is known for Edalen overdose; therefore, management is focused on providing symptomatic and supportive treatment.
  • Monitoring: Continuous cardiovascular monitoring, including ECG monitoring for possible QTc interval prolongation, is required until the patient’s full recovery is clinically confirmed.
  • Mandated Action: Emergency management includes establishing and maintaining a clear airway and ensuring adequate oxygenation and ventilation as first steps.

Regulatory information defines the overdose profile through the consistent documentation of these serious central nervous system and cardiac clinical effects. This mandated structure guides all responders on the documented clinical presentation, the required non-specific, supportive management, and the condition under which urgent help must be sought.

Therapeutic Uses of Edalen

The medication is generally used across three major therapeutic domains. It is applied across domains where additional symptomatic support is needed in conditions characterized by periods of heightened symptoms, including Schizophrenia, acute manic or mixed episodes in Bipolar I Disorder, and irritability associated with Autistic Disorder.

Therapeutic Domains

The medication is commonly used in clinical settings that involve acute or unstable symptom patterns. For conditions like Schizophrenia, it is used to ease pronounced manifestations such as hallucinations and delusions that create noticeable functional strain. In acute episodes of Bipolar I Disorder, it assists with supporting functional stability by managing extreme emotional and physical overactivity, including racing thoughts and sustained irritable or elevated mood. Furthermore, Edalen is relevant for easing intense, disruptive behaviors in pediatric patients, such as severe aggression and self-injurious actions linked to autism. It helps support a sense of stability when symptoms are more noticeable and contributes to easing the overall symptom burden.

“Applied in scenarios where additional management of discomfort is required, Edalen supports the patient during difficult episodes by easing distress and supports a more consistent emotional state.”


Quick Fact: Support for Extreme Emotional and Physical Overactivity

Edalen is commonly used when short-term symptomatic assistance is needed during acute crises, and may help patients cope more steadily with symptom fluctuations across thought, mood, and behavior.

Regulatory References

  1. Risperidone: MedlinePlus Drug Information

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility for Edalen (Risperidone) as defined in government regulatory documents. Eligibility is determined by age, medical status, and the absence of specific contraindications.

Populations Strictly Prohibited

Classification Population Restriction Rationale Context
Contraindicated Patients with known hypersensitivity to risperidone or any of the product components. Known allergy is an absolute exclusion.
Not Approved Elderly patients with dementia-related psychosis. Associated with an increased risk of death and cerebrovascular events (stroke).

Age-Related Eligibility

The medicine's use is officially established for specific minimum ages depending on the condition:

  • Adults are eligible for Schizophrenia and Bipolar I Mania.
  • Adolescents (ge 13 years old) for Schizophrenia.
  • Children and Adolescents (ge 10 years old) for Bipolar I Mania.
  • Children and Adolescents (ge 5 years old) for Irritability associated with Autistic Disorder.

Safety and effectiveness are not established below these age thresholds for each respective indication.

Conditional Use and Special Considerations

Some populations require caution or a lower starting dose as described in the official label:

  • Severe Organ Impairment: Use requires caution in patients with severe renal impairment or severe hepatic impairment, as drug clearance may be reduced.
  • Cardiovascular Conditions: Caution is advised for patients with known cardiovascular disease (e.g., heart failure, history of stroke) or conditions that may lead to hypotension (e.g., dehydration).
  • Pregnancy and Lactation: Exposure during the third trimester of pregnancy may cause withdrawal symptoms in the neonate. Furthermore, the label advises that nursing mothers should not breastfeed.

What should I know about interactions with other medicines?

Interactions with other medicines and products — Official Regulatory Information

The official interaction profile for Edalen (Risperidone) is defined by pharmacokinetic (PK) and pharmacodynamic (PD) patterns documented in government regulatory labeling.

PK Interactions (Exposure Modification):

The metabolism of Edalen involves the CYP2D6 and CYP3A4 enzymes. Co-administration with CYP2D6 inhibitors, such as Fluoxetine and Paroxetine, is documented to increase the plasma concentration of Edalen. Conversely, strong CYP enzyme inducers, including Carbamazepine, Phenytoin, and Rifampin, decrease the active concentration of Edalen. Non-enzyme agents, such as the H2-antagonists Cimetidine and Ranitidine, are also noted to increase Edalen’s bioavailability. Clozapine is documented to decrease the clearance of risperidone.

PD Interactions and Restrictions:

Pharmacodynamic interactions include documented additive effects with other centrally-acting drugs and drugs with hypotensive effects. This requires caution in co-administration. Edalen may also antagonize the effects of Levodopa and other Dopamine Agonists. The substance Alcohol is explicitly advised to be avoided due to enhanced central nervous system effects. Furthermore, official labeling notes that clearance is decreased in populations with Renal or Hepatic Impairment, resulting in increased drug exposure for these groups.

Mechanism of Action

Dual Antagonism: Modulation of Dopaminergic and Serotonergic Signaling

This mechanism focuses on Edalen’s primary action: simultaneous antagonism of the Dopamine D2 receptor and Serotonin 5 -HT2 A receptor. This dual engagement allows the drug to modulate excessive signaling in specific neural pathways involved in cognitive processing. By modulating activity within these central neurotransmitter systems, the antagonistic action on both receptors facilitates a change in signaling dynamics within the targeted neural circuits.

Secondary Receptor Influence and Mechanistic Constraints

Edalen also acts as an antagonist on secondary receptors, including the Adrenergic alpha1 and Histamine H1 receptors, which modulate activity in the autonomic and central arousal pathways. Furthermore, the D2 receptor blockade in the tuberoinfundibular pathway is unopposed by 5 -HT2 A action, leading to a specific, mechanism-driven alteration of the hormonal control over prolactin release. This overall pharmacological profile is defined by both the primary dual antagonism and these secondary receptor-mediated physiological adjustments.

Dosage and Administration Information

How Edalen is Used

Edalen (Risperidone) is a prescription-only medicine used according to guidelines for administration and dosing. The instructions below describe how the medication is used, based on prescribing information.

Administration Routes and Forms

Edalen is administered through two main pathways, depending on the formulation:

Route of Administration Available Forms
Oral Standard Tablets, Oral Solution, Orally Disintegrating Tablets (ODT)
Injection (IM/SC) Extended-Release Injectable Suspension

Oral forms may be taken with or without food. The oral solution can be mixed with specific beverages (e.g., water, coffee, low-fat milk) but should not be mixed with cola or tea. Orally Disintegrating Tablets must be placed immediately on the tongue and not chewed or crushed.

Standard Adult Dosing (Oral)

Dosing is individualized but follows established ranges for acute and maintenance treatment.

Indication Typical Maintenance Range Maximum Daily Dose
Schizophrenia 4-8 mg/day 16 mg/day
Bipolar Mania 1-6 mg/day 6 mg/day

Frequency, Titration, and Special Populations

Oral Edalen is typically taken once or twice daily. The starting dose and any subsequent dose increases (titration) must follow a specified schedule (e.g., increases 24 hours apart). For long-acting injectable forms, administration occurs less frequently (e.g., biweekly or monthly), and the first injection often requires three weeks of oral supplementation to ensure continuous therapeutic coverage.

Specific dosage modifications are required for certain patient groups. Both older adults (geriatric patients) and those with severe renal or hepatic impairment should begin treatment with a reduced starting dose of 0.5 mg twice daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early-Stage Clinical Trials (Phase I/II)

Early-stage research explored the initial scientific rationale for its investigation in a specific autoimmune condition. Studies explored the drug’s observed effects on specific biological markers. These initial trials established dose ranging and monitored participant tolerance. Reports of changes in symptoms were published, but these early trials were small and primarily focused on collecting initial tolerance data.


Main Clinical Trials (Phase III)

Research has primarily focused on the drug's use as a monotherapy or in combination with other existing treatments.

Study 1: Walking Ability and Pain

A multi-center, randomized controlled trial (RCT) involving 600 participants evaluated whether the drug is associated with changes in walking ability and pain levels over a 12-week period.

  • Primary Findings: The study examined the change in scores on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale. In some groups receiving the drug, the outcome reported was associated with differences in pain index scores in some studies compared to the placebo group.
  • Secondary Findings: The trial also examined patient-reported changes in physical function and reports of changes in stiffness over time.

Study 2: Long-Term Outcomes

A follow-up extension study examined long-term outcomes in a subset of participants from Study 1. This open-label research monitored participant tolerance and persistence of reported symptom changes over one year. The study reported outcomes related to the drug but did not confirm sustained clinical benefits across all participants. Data collected included monitoring for adverse events and examination of changes in the SF-36 Health Survey (Quality of Life) scores.

Study 3: Combination Therapy

A separate Phase III trial investigated the use of the drug in combination with another approved treatment over six months. This trial aimed to see if the combination was tolerated. Published findings described changes in joint function scores, but the study did not include a direct comparison to the monotherapy (drug alone) arm.


Context and Guidance

The drug is one of several treatment options for the condition.

Key Studies & References

  1. Open-Label Extension Study of Edalen in Patients with Autoimmune Condition: Safety and Sustained Response Over 52 Weeks (Study 2)

Frequently Asked Questions (FAQ)

Common questions about Edalen (FAQ)


Q: Is Edalen known to cause weight gain?

Official regulatory documents indicate that increased weight gain is a common reaction reported by patients using Edalen. Furthermore, the use of this class of medication has been associated with Metabolic Changes, which can include elevated blood sugar (hyperglycemia) and abnormal cholesterol or fat levels (dyslipidemia).


Q: Why are people talking about a 'black box warning' for Edalen?

The official product label contains a Boxed Warning, which is the strongest caution issued by regulatory agencies. This warning is in place because studies have shown an increased risk of death (primarily from cardiovascular or infectious causes) and Cerebrovascular Adverse Events (such as stroke or mini-stroke) when Edalen is used in older adults with psychosis related to dementia.


Q: How long does Edalen stay in your system after you stop taking it?

Pharmacokinetic data suggests that the combined active form of Edalen takes approximately 20 to 23 hours to reduce its concentration by half (its elimination half-life) for the oral formulations. For the long-acting injectable form, the drug is fully eliminated from the body over a period of several weeks.


Q: Can I take Edalen if I have a pre-existing heart condition?

Official documentation notes that patients with known cardiovascular disease (such as heart failure or a history of stroke) and those with conditions that may lead to low blood pressure (hypotension) require careful monitoring. These risks are particularly relevant during the initial phase of treatment.


Q: Can I use Edalen if I am trying to become pregnant?

The regulatory label indicates that exposure to Edalen during the third trimester of pregnancy may cause withdrawal symptoms or movement problems in the newborn (neonate). For this reason, a pregnancy registry is available to help monitor and collect information on outcomes in women who have been exposed to the medication during pregnancy.


Q: Is Edalen a type of drug that needs regular blood tests?

Official safety guidance indicates the need for monitoring due to potential side effects. Patients should be monitored for signs of hyperglycemia (high blood sugar) and dyslipidemia (abnormal blood fat levels) because of documented metabolic changes. Furthermore, monitoring of white blood cell counts is advised for patients with a history of low counts.


Q: Does Edalen interact with herbal supplements like St. John's Wort?

While the official drug interaction profile lists specific prescription medications that affect how the drug is metabolized, it does not specifically list common herbal supplements. General caution is noted when this medicine is co-administered with products that may influence drug metabolism.


Q: Is it okay to drink coffee or tea while using Edalen?

Official instructions for the oral solution state that it should not be mixed with cola or tea. However, the oral forms of the medication are generally noted to be taken with or without food or beverages, and absorption is not significantly affected by meals.


Q: What is the main difference between Edalen and other drugs that treat the same condition?

Edalen is classified by regulatory bodies as an Atypical Antipsychotic (Second-Generation Antipsychotic). It is distinguished by its dual-action profile, which involves blocking both dopamine and serotonin receptors simultaneously.


Q: Do you take Edalen every day or only as needed?

Official dosing information states that oral Edalen is typically taken on a once-daily or twice-daily basis. The long-acting injectable forms are administered less frequently (e.g., biweekly or monthly). This medicine is prescribed for scheduled treatment and not for as-needed use.


Q: How quickly can I expect to notice any effects from Edalen?

After taking the oral form, the peak concentration in the blood is typically reached within 1 to 2 hours. For the extended-release injection, the drug's major therapeutic release does not begin until approximately 3 weeks after the first injection, which means oral supplementation is necessary during that period to achieve continuous therapeutic coverage.


Q: What happens if I stop taking Edalen suddenly?

Regulatory documents state that patients who stop the medication abruptly may experience various symptoms, including nausea, vomiting, anxiety, agitation, and restlessness. A gradual reduction in dose (tapering) is often used to manage these discontinuation symptoms.


Q: Are there any specific foods I should avoid while on Edalen?

The official regulatory information indicates that the absorption of the oral formulation is not affected by food, and it can be taken with or without meals. Specific dietary restrictions are not generally required, apart from the restriction on mixing the oral solution with certain beverages.


Q: Is Edalen considered a long-term medication?

The drug is officially indicated and used for the maintenance treatment of certain conditions, such as Schizophrenia and Bipolar I Disorder. Therefore, it can be used on a long-term basis, as determined by a healthcare provider.


Q: What happens if a child accidentally takes Edalen?

Official safety information advises that if an accidental overdose is suspected, people should immediately contact a poison control center or seek care at an emergency room.


Q: Is Edalen an addictive substance?

The official regulatory information does not classify Edalen as a controlled substance under federal law. Furthermore, the label does not list it as having a known potential for abuse or physical dependence.


Q: How long does the primary effect of a single Edalen dose last?

The half-life of the active component is approximately 20 to 23 hours. This pharmacological characteristic supports the typical clinical practice of prescribing the medicine on a once-daily or twice-daily schedule.


Q: How does the time of day I take Edalen influence its effectiveness?

The medicine is prescribed on a set schedule to ensure consistent drug levels. A healthcare provider can determine whether the medicine should be taken in the morning or evening to best manage potential side effects.


Q: How is Edalen different from a drug that works by a 'similar mechanism'?

Edalen is categorized as a Second-Generation Antipsychotic. Its key difference from older, 'First-Generation' agents is its dual-action of blocking both serotonin and dopamine receptors, and this balance is considered the defining characteristic of the atypical class.


Q: Are there any common reasons why a patient might stop taking Edalen?

Official reports from clinical trials indicate that adverse reactions were the most common reasons for participants to discontinue treatment. Reactions most frequently associated with discontinuation included agitation, depression, anxiety, and akathisia (a movement disorder).


Q: What is the common misunderstanding about how Edalen should be used?

One key instruction for the long-acting injectable form is the requirement for a three-week overlap with oral dosing following the first injection. This use condition is important for achieving continuous therapeutic coverage and is sometimes a point of clarification for patients.


Q: Do you need a special prescription for Edalen?

Edalen is officially classified as a prescription-only medicine. It is not listed as a controlled substance under federal law, meaning it does not typically require the special handling or forms associated with scheduled narcotics or drugs of abuse.


Q: Is it normal to have a slight headache when first starting Edalen?

According to regulatory safety data, headache is listed as a very common adverse reaction, meaning it is reported in a significant portion of patients. Furthermore, effects like dizziness upon standing (Orthostatic Hypotension) are noted to be more likely to occur in the initial phase of treatment.


Q: Can people with diabetes use Edalen safely?

Patients who have diabetes or are considered at risk for developing it should have their blood glucose monitored regularly. This is advised because the medication has been associated with hyperglycemia (high blood sugar) and new-onset diabetes mellitus.

How should Edalen be stored and disposed of?

How to Store and Dispose of Edalen?

Official regulatory documents define specific storage and stability requirements for both Edalen formulations:

  • Intravenous (IV) Injection: The overwrap package contains an oxygen indicator. The product must not be used if this indicator has turned blue or purple before the package is opened. Once the overwrap is opened, the injection must be administered within 24 hours. Prior to use, the solution must be visually inspected for particulate matter or discoloration.

  • Oral Suspension: This formulation requires storage at room temperature and must be protected from light. The stability period after the bottle is opened is limited; any unused portion must be discarded 15 days after opening or 30 days from the date of shipment indicated on the pharmacy carton label, whichever is earlier.

Disposal should be carried out according to the specific time limits defined by the product's in-use stability, ensuring unused medication is safely discarded after the mandated period.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Edalen found in:

A-Z Index: